EOSINOPHILIC ESOPHAGITIS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Eosinophilic esophagitis is a chronic condition which is treated with the help of steroids and acid suppressants such as proton pump inhibitors. Steroids help control the inflammation. Topical steroids are administered as a inhaler or as a liquid. Oral steroids may be prescribed to treat people who have serious swallowing problems or weight loss. Proton pump inhibitors help with reflux symptoms and decrease inflammation.

Market Dynamics

Growing awareness regarding eosinophilic esophagitis leads to an increase in demand for treatment products. Thus, key market players are engaged in developing newer treatments and addressing the demand for EoE treatment products. For instance, Sanofi S.A. a global biopharmaceutical company engaged in conducting a phase 3 clinical trial for Dupixent (dupilumab) and is estimated to complete by 2024. Additionally, upcoming innovative products to improve the management of EoE are anticipated to drive the global market growth. For instance, in December 2021, Takeda Pharmaceutical Company Limited a Japanese multinational pharmaceutical company received a Complete Response Letter (CRL) for TAK-721 (budesonide oral suspension) from the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis. In June 2021, the U.S. FDA granted Orphan Drug Designation (ODD) for Etrasimod. Etrasimod had been investigated by Arena Pharmaceuticals, Inc. an American biopharmaceutical company. Moreover, an increase in the prevalence of eosinophilic esophagitis is likely boost the market growth. For instance, according to a study published in the Saudi Medical Journal in July 2018, eosinophilic esophagitis is an emerging disease and has an increasing incidence in children in Saudi Arabia.

Key features of the study:

• This report provides an in-depth analysis of the global eosinophilic esophagitis market, market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2020 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global eosinophilic esophagitis market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
• Key companies covered as a part of this study include Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global eosinophilic esophagitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global eosinophilic esophagitis

Detailed Segmentation:

• Global Eosinophilic Esophagitis Market, By Drug Class:
  • Corticosteroids
    • Budesonide
      • Jorveza
      • Off-label budesonide
    • Fluticasone
  • Proton Pump Inhibitor (PPI)
    • Omeprazole
    • Esomeprazole
    • Others
  • Late Stage Pipeline Drugs
    • Dupixent
    • APT-1011
    • Lirentelimab (AK002)
    • Cendakimab
    • Etrasimod
    • TAK-721
    • Omilancor (BT-11)
• Global Eosinophilic Esophagitis Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Eosinophilic Esophagitis Market, By Region:
  • North America
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • GlaxoSmithKline plc*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Ellodi Pharmaceuticals
  • EsoCap AG
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Sun Pharmaceutical Industries Limited
  • AstraZeneca Plc
  • Sanofi S.A.
  • Arena Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Revolo Biotherapeutics
  • Allakos Inc.
  • Bristol-Myers Squibb Co
  • Calypso Biotech
  • DBV Technologies
  • Landos Biopharma, Inc.
  • Glenmark Pharmaceuticals
  • Alkem Laboratories Ltd.
  • Quorum Innovations LLC
  • Dr. Falk Pharma GmbH

“*” marked represents similar segmentation in other categories in the respective section.